Viridian Therapeutics (VRDN) said Monday that a late-stage trial of candidate drug veligrotug met all of its primary and secondary endpoints for symptoms of chronic thyroid eye disease.

Viridian said about 56% of the trial's veligrotug-treated patients experienced a reduction in proptosis or the abnormal bulging of eyes, with a 2.34 mm mean reduction.

Additionally, 56% of the veligrotug population experienced a reduction in diplopia or double vision, with 32% achieving complete resolution, the company said.

The trial resulted in a 2.9-point mean reduction in inflammatory signs and symptoms from baseline, Viridian said.

Veligrotug was generally well-tolerated, with only mild adverse events, Viridian said.

Price: 21.20, Change: +3.35, Percent Change: +18.32